中國自1978年改革開放以來，高昂的醫療支出和虛高的藥價一直是影響民生的重大問題。2018年爆火的內地電影《我不是藥神》，就反映了許多癌症患者面臨的困境：單價近萬元的標靶藥物讓他們望而卻步。有鑑於此，中國政府近年來對藥價管理機制進行革命性的改革，取得了巨大成效。
14 Jun 2023
教學人員
Prof. Wen ZHOU
管理及商業策略
Associate Professor
Associate Director, Asia Case Research Centre
3917 5665
KK 1225
Academic & Professional Qualification
- PhD in Economics, Duke University
- MA in Economics, Peking University
- BSc in Biology, University of Science & Technology of China
Biography
Dr. Wen Zhou is an Associate Professor in the group of Management and Strategy, HKU Business School. He received BS in biology from the University of Science and Technology of China, MA in economics from Peking University and PhD in economics from Duke University. He joined the University of Hong Kong in 2007 after working at the Hong Kong University of Science and Technology for several years.
Teaching
Dr. Zhou teaches Managerial Economics for MBA, IMBA, and EMBA.
Research Interest
Dr. Zhou is an economist working in the field of industrial organization. His research focuses on endogenous market structure in the presence of mergers, innovation, and international trade. He has also studied business strategies such as pricing and advertising.
Selected Publications
- “Creating a merger option to strategically prevent a merger among suppliers or customers”, with Lezhen Wu, Dingwei Gu and Zhiyong Yao, Naval Research Logistics, 2023, Forthcoming. https://doi.org/10.1002/nav.22148
- “Sequential Mergers Under Incomplete Information”, with Jiajia Cong, Journal of Economics and Management Strategy, 2023, Forthcoming. https://doi.org/10.1111/jems.12549
- “Proportional Fee vs. Unit Fee: Competition, Welfare, and Incentives”, with Dingwei Gu and Zhiyong Yao, Journal of Industrial Economics, 2022, Vol. 70, No. 4, pp. 999-1032. https://doi.org/10.1111/joie.12279
- “Inflexible Repositioning: Commitment in Competition and Uncertainty”, with Jiajia Cong, Management Science, 2020, Vol. 66, No. 9, pp. 4207-4225. https://doi.org/10.1287/mnsc.2019.3383
- “Vertical Integration and Disruptive Cross-market R&D”, with Ping Lin and Tianle Zhang, Journal of Economics and Management Strategy, 2020, Vol. 29, No. 1, pp. 51-73. https://doi.org/10.1111/jems.12328
- “When is Upstream Collusion Profitable?”, with Dingwei Gu, Zhiyong Yao, and Rangrang Bai, RAND Journal of Economics, 2019, Vol. 50, No. 2, pp. 326-341. https://doi.org/10.1111/1756-2171.12271
- “Entry, Reputation and Intellectual Property Rights Enforcement”, with Jiahua Che and Larry Qiu, Canadian Journal of Economics, 2014, Vol. 47, No. 4, pp. 1256-1281. https://doi.org/10.1111/caje.12104
- “Multiproduct Firms and Scope Adjustment in Globalization”, with Larry Qiu, Journal of International Economics, 2013, Vol. 91, No. 1, pp. 142-153. https://doi.org/10.1016/j.jinteco.2013.04.006
- “The Effects of Competition on the R&D Portfolios of Multiproduct Firms”, with Ping Lin, International Journal of Industrial Organization, 2013, Vol. 31, No. 1, pp. 83-91. https://doi.org/10.1016/j.ijindorg.2012.11.003
- “Endogenous Horizontal Mergers under Cost Uncertainty”, International Journal of Industrial Organization, 2008, Vol. 26, No. 4, pp. 903-912. https://doi.org/10.1016/j.ijindorg.2006.10.010
- “Large is Beautiful: Horizontal Mergers for Better Exploitation of Production Shocks”, Journal of Industrial Economics, 2008, Vol. 56, No. 1, pp. 68-93. https://doi.org/10.1111/j.1467-6451.2008.00333.x
- “Merger Waves: A Model of Endogenous Mergers”, with Larry Qiu, RAND Journal of Economics, 2007, Vol. 38, No. 1, pp. 214-226. https://doi.org/10.1111/j.1756-2171.2007.tb00052.x
- “International Mergers: Incentives and Welfare”, with Larry Qiu, Journal of International Economics, 2006, Vol. 68, No. 1, pp. 38-58. https://doi.org/10.1016/j.jinteco.2004.12.005
- “The Choice of Commercial Breaks in Television Programs: The Number, Length, and Timing”, Journal of Industrial Economics, 2004, Vol. 52, No. 3, pp. 315-326. https://doi.org/10.1111/j.0022-1821.2004.00228.x
Recent Publications
14Jun
14Jun
中國自1978年改革開放以來，高昂的醫療支出和虛高的藥價一直是影響民生的重大問題。2018年爆火的內地電影《我不是藥神》，就反映了許多癌症患者面臨的困境：單價近萬元的標靶藥物讓他們望而卻步。有鑑於此，中國政府近年來對藥價管理機制進行革命性的改革，取得了巨大成效。
14 Jun 2023
管理及商業策略
19Oct
西區海底隧道（西隧）專營權明年8月屆滿，政府計劃繼接收西隧後，在三條過海隧道實施「擠塞徵費」。這個方案向立法會提出後，社會上出現一些反對意見。其實，按照擠塞程度分段收費，是各種方案中比較科學可行的一種，也是世界各大城市公共交通政策的共同趨勢。
19 Oct 2022
教學人員
19Oct
西區海底隧道（西隧）專營權明年8月屆滿，政府計劃繼接收西隧後，在三條過海隧道實施「擠塞徵費」。這個方案向立法會提出後，社會上出現一些反對意見。其實，按照擠塞程度分段收費，是各種方案中比較科學可行的一種，也是世界各大城市公共交通政策的共同趨勢。
19 Oct 2022
管理及商業策略
21Sep
近年美國民意兩極化，許多社會重大問題如槍械管制、墮胎等難以化解。民眾的分歧，本該以少數服從多數的原則，在國會通過立法來解決，但這一原則常常無法奏效。少數派的拿手絕活是「拉布」，亦即通過長時間發言、討論，阻止對某項法案投票以至法案的通過。從古羅馬到當今各國議會，包括香港特區立法會的不同黨派，都使用過這種手段。美國國會參眾兩院則只有參議院可以拉布，這自然成為法案通過的重要關卡。
21 Sep 2022
教學人員
21Sep
近年美國民意兩極化，許多社會重大問題如槍械管制、墮胎等難以化解。民眾的分歧，本該以少數服從多數的原則，在國會通過立法來解決，但這一原則常常無法奏效。少數派的拿手絕活是「拉布」，亦即通過長時間發言、討論，阻止對某項法案投票以至法案的通過。從古羅馬到當今各國議會，包括香港特區立法會的不同黨派，都使用過這種手段。美國國會參眾兩院則只有參議院可以拉布，這自然成為法案通過的重要關卡。
21 Sep 2022
管理及商業策略
29Jun
男子組合MIRROR的演唱會即將開始，全城早已掀起搶票潮，粉絲卻苦於一票難求。即使另加兩場特別場，採用實名制售票，依然無法阻止黃牛黨瘋狂炒票。公開發售的門票瞬間售罄，有本地傳媒報道，二手市場上的黃牛票竟被炒到40多萬元，粉絲們自然叫苦連天。
29 Jun 2022
教學人員
29Jun
男子組合MIRROR的演唱會即將開始，全城早已掀起搶票潮，粉絲卻苦於一票難求。即使另加兩場特別場，採用實名制售票，依然無法阻止黃牛黨瘋狂炒票。公開發售的門票瞬間售罄，有本地傳媒報道，二手市場上的黃牛票竟被炒到40多萬元，粉絲們自然叫苦連天。
29 Jun 2022
市場學